Molecular pathways and therapeutic targets in lung cancer.

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget (2015) 1.31

Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02

Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol (2015) 0.89

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget (2015) 0.86

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget (2015) 0.86

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget (2016) 0.85

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget (2016) 0.83

High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget (2014) 0.81

Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC. Oncotarget (2016) 0.81

Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn (2016) 0.80

Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer. Oncotarget (2017) 0.80

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. Oncotarget (2016) 0.79

Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res (2015) 0.79

A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types. Clin Transl Med (2015) 0.78

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget (2016) 0.76

The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus (2016) 0.75

MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4. Sci Rep (2016) 0.75

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. Oncotarget (2016) 0.75

Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Elife (2016) 0.75

Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells. Oncotarget (2016) 0.75

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. Oncotarget (2016) 0.75

Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling. Int J Clin Exp Pathol (2015) 0.75

The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther (2015) 0.75

MicroRNA-148a suppresses proliferation and invasion potential of non-small cell lung carcinomas via regulation of STAT3. Onco Targets Ther (2017) 0.75

The roles of ARHGAP10 in the proliferation, migration and invasion of lung cancer cells. Oncol Lett (2017) 0.75

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians. Oncotarget (2017) 0.75

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One (2017) 0.75

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68

Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol (2004) 8.94

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56

BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55

Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08

LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09

RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23

Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature (2003) 6.07

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04

DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature (2013) 5.04

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol (2008) 4.86

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80

LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43

KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38

AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89

Binding of GAP to activated PDGF receptors. Science (1990) 3.89

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (1994) 3.87

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene (2009) 3.86

Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A (2007) 3.84

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol (2013) 3.69

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst (2013) 3.63

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48

PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42

Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 3.35

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol (2010) 3.26

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25

Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst (2013) 3.24

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23

The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02

Notch-dependent differentiation of adult airway basal stem cells. Cell Stem Cell (2011) 2.95

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89

The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell (2013) 2.87

Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79

Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64

Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet (2009) 7.07

Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69

Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75

The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68

PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06

Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93

Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res (2002) 3.90

Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78

Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest (2005) 3.55

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet (2011) 3.25

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett (2004) 3.17

Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83

c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73

Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56

Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg (2004) 2.53

Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol (2003) 2.45

Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res (2003) 2.39

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36

The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev (2004) 2.23

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov (2011) 2.22

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19

A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet (2003) 2.18

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev (2002) 2.08

c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06

Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06

Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol (2003) 2.04

Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03

Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis (2005) 2.02

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01

Lung cancer screening. J Natl Compr Canc Netw (2012) 2.00

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2011) 1.99

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res (2009) 1.91

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90

Management of High-Throughput DNA Sequencing Projects: Alpheus. J Comput Sci Syst Biol (2008) 1.85

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84

Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc (2003) 1.83

Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg (2004) 1.82

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res (2002) 1.82

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81

Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J (2012) 1.80

Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann Thorac Surg (2006) 1.79

Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79

Modified T-tube repair of delayed esophageal perforation results in a low mortality rate similar to that seen with acute perforations. Ann Thorac Surg (2007) 1.78

Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A (2006) 1.75

Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res (2009) 1.73

Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep (2009) 1.73

PTEN hamartoma tumor syndromes. Eur J Hum Genet (2008) 1.72

Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst (2006) 1.72

Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71

Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res (2004) 1.69

Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab (2013) 1.68

Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res (2006) 1.64

Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64

Semi-supervised recursively partitioned mixture models for identifying cancer subtypes. Bioinformatics (2010) 1.63

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res (2006) 1.61

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol (2003) 1.61

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res (2008) 1.60

Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol (2005) 1.60

Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst (2003) 1.59

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res (2007) 1.59

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun (2009) 1.58

Targeting Akt in cancer therapy. Anticancer Drugs (2007) 1.57

Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg (2003) 1.56

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol (2006) 1.55

5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem (2004) 1.54

CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem (2007) 1.53

Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet (2009) 1.52

Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.51

Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res (2004) 1.51

Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol (2008) 1.51

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res (2005) 1.50

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep (2007) 1.50

Antireflux operation for gastroesophageal reflux after Roux-en-y gastric bypass for obesity. Ann Thorac Surg (2005) 1.49

Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys (2002) 1.49